Conference Calls and Earnings Call Transcripts for NSE and BSE Stocks

Conference Call with Crompton Greaves Consumer Management and Analysts on Q4FY20 and Full Year Earnings Performance and Outlook. Listen in to the full earnings transcript.

Conference Call with Aarti Drugs Management and Analysts on Q4FY20 and Full Year Earnings Performance and Outlook. Listen in to the full earnings transcript.

Conference Call with Cipla Management and Analysts on Q4FY20 and Full Year Earnings Performance. Listen in to the full earnings transcript.

Conference Call with Nippon Life Management and Analysts on Q4FY20 and Full Year Earnings Performance and Outlook. Full earnings call.

Conference Call with Biocon Limited Management and Analysts on Q4FY20 Earnings and Outlook. Listen in to the full earnings transcript

• We are adequately stocked with critical inventory to manufacture our strategic requirements. In small molecules we have discontinued non strategic molecules where materials were sourced from China, and their facilities repurposed for strategic molecules. 

• After three strong quarters, Biocon had a weak fourth quarter, due to a challenging period for Biologics. Our small molecules and research segments delivered very strong growth.  

• Volumes of generics and biosimilars have huge opportunities to ramp up post Covid, we have a real opportunity once things normalize. 

• In Q1FY21 we expect financial performance to improve over Q4. We expect an uptick in growth visible in numbers from Q2 onwards. 

• FDA approvals for upcoming biosimilar is expected shortly. This adds to the growing portfolio of biosimilars in partnership with Mylan.

• Our biologics facilities in india and Malaysia have received EIRs from the US FDA and EMA.

• Q4FY20 revenues increased by 6% YoY; revenues from operations was up 3%. Small molecules was up 15%, research services up 14%. Biologics was impacted by COVID19 with branded formulations declining by 12%. Increase in R&D spend seen on account of higher spends on biosimilars and insulin. Forex gain of Rs 35 crores this quarter due to rupee depreciation against the dollar. Has been shown in Other Income.

• EBTIDA Margins is at 23%. Increase in operating costs, higher R&D spend, higher staff costs, increase in operating cost in Malaysia have hit margins. Core margins stood at 29%. 

• FY20 revenue consolidated grew 15% YoY. Revenues from operations were up 15%, small molecules crossed Rs. 2000 crore milestone, up 18%. Biologics had strong annual growth of 29% (at Rs 1,951 crore) . Branded formulations declined 18% YoY. Syngene reported 10% revenue growth - again crossed Rs. 2000 crore milestone.